{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:30:33Z","timestamp":1792315833115,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.schres.2017.07.033","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T03:00:35Z","timestamp":1500606035000},"page":"23-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method"],"prefix":"10.1016","volume":"193","author":[{"given":"Philipp H.","family":"Rothe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2017.07.033_bb0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.07.033_bb0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0924-9338(15)30222-4","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"Berwaerts","year":"2015","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.07.033_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2017.07.033_bb0020","series-title":"British National Formulary","author":"Committee","year":"2012"},{"key":"10.1016\/j.schres.2017.07.033_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-3956(74)90071-5","article-title":"Dose equivalence of the anti-psychotic drugs","volume":"11","author":"Davis","year":"1974","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.07.033_bb0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2017.07.033_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001951","article-title":"Haloperidol dose for the acute phase of schizophrenia","volume":"2","author":"Donnelly","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"issue":"discussion S12-15","key":"10.1016\/j.schres.2017.07.033_bb0040","first-page":"S7","article-title":"Minimal effective dose and relapse\u2013double-blind trial: haloperidol decanoate vs. placebo","volume":"14","author":"Eklund","year":"1990","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.schres.2017.07.033_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study","volume":"205","author":"Fleischhacker","year":"2014","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.07.033_bb0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4088\/JCP.14m09416","article-title":"Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder","volume":"76","author":"Fu","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2017.07.033_bb0060","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.schres.2017.07.033_bb0065","series-title":"International Consensus Study of Antipsychotic Dosing","author":"Gardner","year":"2014"},{"issue":"5","key":"10.1016\/j.schres.2017.07.033_bb0070","doi-asserted-by":"crossref","first-page":"1,478","DOI":"10.4088\/JCP.v66n0515","article-title":"Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder","volume":"66","author":"Glick","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.07.033_bb0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":"Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"25","author":"Gopal","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2017.07.033_bb0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"Am. J. Psychiatr."},{"issue":"4","key":"10.1016\/j.schres.2017.07.033_bb0090","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/appi.ajp.159.4.554","article-title":"A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia","volume":"159","author":"Kane","year":"2002","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.schres.2017.07.033_bb0095","first-page":"181","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"167.2","author":"Kane","year":"2009","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.schres.2017.07.033_bb0100","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160.6","author":"Kane","year":"2003","journal-title":"Am. J. Psychiatr."},{"issue":"Suppl. 12","key":"10.1016\/j.schres.2017.07.033_bb0105","first-page":"5","article-title":"Expert consensus guidelines for optimizing pharmacologic treatment of psychotic disorders","volume":"64","author":"Kane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.07.033_bb0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"73","author":"Kane","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.07.033_bb0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2017.07.033_bb0125","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbn110","article-title":"What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?","volume":"36","author":"Kemp","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2017.07.033_bb0130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.10m06191","article-title":"Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications","volume":"72","author":"Khin","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.07.033_bb0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.07.033_bb0140","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S1461145709990988","article-title":"Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study","volume":"13","author":"Kramer","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9896","key":"10.1016\/j.schres.2017.07.033_bb0150","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"9657","key":"10.1016\/j.schres.2017.07.033_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2017.07.033_bb0160","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2017.07.033_bb0165","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/schbul\/sbv037","article-title":"Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2017.07.033_bb0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.07.033_bb0175","series-title":"Risperidone Dose for Schizophrenia (Review)","author":"Li","year":"2012"},{"key":"10.1016\/j.schres.2017.07.033_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007778","article-title":"Chlorpromazine dose for people with schizophrenia","volume":"2","author":"Liu","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.schres.2017.07.033_bb0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13651500510028995","article-title":"A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance","volume":"9","author":"MacE","year":"2005","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"8","key":"10.1016\/j.schres.2017.07.033_bb0190","doi-asserted-by":"crossref","first-page":"1,478","DOI":"10.4088\/JCP.14m09741","article-title":"A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia","volume":"76","author":"Meltzer","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.07.033_bb0195","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1192\/pb.19.9.575-a","article-title":"Neuroleptic prescribing practice","volume":"19","author":"Milton","year":"1995","journal-title":"Psychiatr. Bull."},{"issue":"9","key":"10.1016\/j.schres.2017.07.033_bb0200","first-page":"575","article-title":"Neuroleptic prescribing practice","volume":"19","author":"Milton","year":"1995","journal-title":"Psychiatrist"},{"issue":"10","key":"10.1016\/j.schres.2017.07.033_bb0205","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":"A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2017.07.033_bb0210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","article-title":"Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study","volume":"36","author":"Nasser","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2017.07.033_bb0215","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"3","key":"10.1016\/j.schres.2017.07.033_bb0220","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2017.07.033_bb0225","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.schres.2013.06.030","article-title":"How to compare doses of different antipsychotics: a systematic review of methods","volume":"149","author":"Patel","year":"2013","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2017.07.033_bb0230","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone study group","volume":"166","author":"Peuskens","year":"1995","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.07.033_bb0235","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.euroneuro.2013.03.006","article-title":"The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia","volume":"23","author":"Spineli","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2017.07.033_bb0240","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2147\/NDT.S54051","article-title":"Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia","volume":"8","author":"Takahashi","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2017.07.033_bb0245","series-title":"WHO. Collaborating Centre for Drug Statistics Methodology","author":"WHO","year":"2012"},{"issue":"6","key":"10.1016\/j.schres.2017.07.033_bb0250","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417304449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417304449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T02:48:02Z","timestamp":1569898082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417304449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":46,"alternative-id":["S0920996417304449"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.07.033","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}